Genmab AS
Company Profile
Business description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Contact
Carl Jacobsens Vej 30
Valby2500
DNKT: +45 70202728
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3,029
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
stocks
Chart of the Week: US equity market trading at an attractive discount
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,203.24 | 60.63 | -0.73% |
| DAX 40 | 23,712.39 | 368.24 | -1.53% |
| Dow JONES (US) | 47,867.32 | 42.60 | -0.09% |
| FTSE 100 | 10,586.43 | 22.45 | -0.21% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,571.03 | 63.97 | -0.28% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,774.43 | 8.38 | -0.12% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |